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Abstract
Antithrombin (AT) belongs to the serpin family and is a key
regulator of the coagulation system. AT inhibits active clot-
ting factors, particularly thrombin and factor Xa; its absence
is incompatible with life. This review gives an overview of
the protein and gene structure of AT, and attempts to explain
how glucosaminoglycans, such as heparin and heparan sul-
fate accelerate the inhibitory reaction that is accompanied by
drastic conformational change. Hypotheses on the regulation
of blood coagulation by AT in physiological conditions are
discussed. Epidemiology of inherited thrombophilia caused
by AT deficiency and its molecular genetic background with
genotype-phenotype correlations are summarized. The im-
portance of the classification of AT deficiencies and the phe-
notypic differences of various subtypes are emphasized. The
causes of acquired AT deficiency are also included in the
review. Particular attention is devoted to the laboratory diag-
nosis of AT deficiency. The assay principles of functional
first line laboratory tests and tests required for classification
are discussed critically, and test results expected in various
AT deficiency subtypes are summarized. The reader is pro-
vided with a clinically oriented algorithm for the correct
diagnosis and classification of AT deficiency, which could
be useful in the practice of routine diagnosis of
thrombophilia.
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Introduction
The stepwise discovery of antithrombin (AT, SERPINC1) is
an exciting story. A detailed account and chronology of the
most important events leading to the foundation of our pres-
ent knowledge about this essential inhibitor of blood co-
agulation has recently been in an excellent review by
Abildgaard (1), recommended for readers interested in this
subject. Here, only the issue of nomenclature is mentioned.
In the earlier literature, AT used to be termed antithrombin
III to distinguish the protein from other proteins with anti-
thrombin activity. Antithrombin I is the thrombin absorbing
capacity of fibrin (2) and antithrombin II, more frequently
termed heparin cofactor II (SERPIND1) which is another
inhibitor of thrombin in plasma (3). Although this is not the
only antithrombin present in plasma, we adopted the current
nomenclature and use the terms antithrombin and AT through-
out the article.
AT is a single-chain glycoprotein with a molecular mass
of 58,200 Da. The mature protein consists of 432 amino
acids with three internal disulfide bonds. As much of the
literature and the existing databases use traditional amino
acid residue numbering, starting with the N-terminal residue
of the mature protein, we used this system in the article. The
numbering system recommended by the Human Genome
Variation Society (HGVS) starts with the initiator methio-
nine. In the case of AT, HGVS numbering can be calculated
by adding 32, corresponding to the 32 amino acid residues
of the leader sequence, to the traditional number. AT has two
isoforms which differ only in the extent of glycosylation (4,
5). The a isoform is N-glycosylated on four Asn residues
(95, 135, 155 and 192), while the b isoform lacks glyco-
sylation on Asn135. The a variant is the major AT isoform
(90%–95%) in the circulation, the b isoform represents only
5%–10% of AT in plasma. AT is synthesized in the liver, its
half-life in the circulation is approximately 2.4 days. A
prominent feature of AT is its high affinity binding to neg-
atively charged glycosaminoglycans (GAGs) such as heparin
or heparan sulfate which contain specific pentasaccharide
units. Due to the lack of carbohydrate residue on Asn135,
the b isoform binds to GAGs with higher affinity. Heparan
sulfate in the form of heparan sulfate proteoglycane (HPSG)
is present on the surface of vascular endothelium. Thus, a
higher portion of the b isoform becomes cleared from the
circulation and targets the vessel wall.
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The structure of antithrombin and structural
changes during its interaction with active
clotting factors
The atomic 3D structure of native AT was resolved approx-
imately 15 years ago (6, 7). Since then, numerous AT struc-
tures have been published which have helped in the
understanding of how AT exerts its inhibitory function
(8–14). AT belongs to the family of serine protease inhibitors
(serpins), the largest family of protease inhibitors that con-
sists of over 1500 members (4, 14, 15). These are single
chain globular proteins that consist of 300–500 amino acid
residues and show about 30% sequence identity. Serpins
share a common tertiary structure; they contain three
b-sheets (A-C) and eight to nine a-helices (A-I). A flexible
peptide loop, reactive center loop (RCL) containing the reac-
tive site, is exposed on the top of the molecule. RCL contains
a sequence which is complementary to the active site of the
target protease. All serpins feature significant structural flex-
ibility, which allows dramatic structural changes upon reac-
tion with the protease to be inhibited. These are so-called
suicide inhibitors. The target protease cleaves a scissile bond
in RCL and then it remains covalently linked to the inhibitor.
Antithrombin is a misnomer, the inhibitory effect of AT is
not restricted to thrombin. It is a polyvalent serpin that also
inhibits activated factor X (FXa) and to a lesser extent a
whole series of serine proteases involved in the hemostatic
machinery, including FIXa, FXIa, FXIIa, plasmin and kallik-
rein (4, 5). AT inactivates FVIIa only when it is bound to
tissue factor (16–18). AT is a co-called progressive inhibitor;
the rate of its reaction with the active coagulation factors is
slow, but in the presence of heparin or HPSG, the rate of
inhibition is accelerated 500-fold.
AT has a typical serpin secondary and tertiary structure.
It consists of nine helices and three b-sheets (Figure 1). In
the uncleaved form, it can exist in two main conformational
states. In the native uncleaved form, the 24-membered RCL
with the scissile P1-P1’ (Arg393-Ser394) bond is outside the
main body of AT (Figure 1A). In the latent conformation,
the RCL is inserted into the b-sheet. The latter conformation
is thermodynamically more stable than the native form,
which is kinetically ‘‘trapped’’ in a high energy state. AT
circulates primarily in this kinetically trapped native form.
The X-ray structure of this conformation revealed that the
P1 residue (Arg393) points to the surface of the body of AT,
and the P14-P15 residues are inserted into b-sheet A, which
constrains the RCL and allows contacts between the P1 argi-
nine side chain and the body of AT. Having such a rigid
conformation of RCL, AT is a poor inhibitor of FXa or
thrombin, and is unable to inhibit FIXa.
The binding of pentasaccharide or heparin containing the
pentasaccharide unit causes remarkable changes of the con-
formation of RCL and its close proximity (Figure 2B). The
entrapped part of RCL is expulsed from b-sheet A, the end
of the third b-strand of b-sheet A moves closer to the fifth
b-strand and helix D becomes elongated. The interaction
between AT and the pentasaccharide unit takes place in two
steps (not shown on Figure 2); an initial weak binding inter-
mediate becomes transformed into a high binding state with
1000-fold higher affinity. The latter conformation is neces-
sary for the effective formation of the Michaelis complex
(Figure 2C) between AT and FXa or FIXa, in which Arg393
of AT and the region in its immediate vicinity is recognized
by the protease as a substrate loop. The mechanism of
Michaelis complex formation between thrombin and AT is
somewhat different. In this case, the conformational change
induced by the allosteric effect of pentasaccharide is not suf-
ficient, and probably not even required. Thrombin also binds
to heparin, and the bridging effect of heparin of 18 saccha-
ride units or longer, which brings thrombin and AT together,
is essential for effective interaction (11, 22, 23).
After the rate-controlling Michaelis complex formation,
the inhibition of active coagulation factors follows the gen-
eral scheme of serpin action. In the first step of proteolytic
reaction, an acyl-enzyme intermediate is formed through an
ester bond between Arg393 and the active site serine of the
protease. AT undergoes a rapid, drastic and irreversible con-
formational change where the P14-P3 part of RCL becomes
incorporated into b-sheet A as an additional strand (Figure
2D), and AT assumes a cleaved relaxed form. This process
is accompanied by a 1000-fold reduction in heparin affinity
and by a large-scale conformational change in the acyl-
enzyme complex. The protease which is covalently tethered
to Arg393 becomes transported from the top to the bottom
of AT, approximately 70 A˚ away from its original position.
Due to the distortion of the active site of the protease, the
acyl intermediate becomes stabilized and the second step of
proteolytic reaction, the release of the cleaved peptide, can-
not take place. In this process the protease structure becomes
disrupted and the catalytic triad distorted. Only very slow
release of the inactive inhibitor and enzyme can be detected
from the AT-protease complex (24).
The role of antithrombin in the regulation of
coagulation
AT serves as a highly important regulator of hemostasis; its
absence is incompatible with life (5). The primary actions of
AT are the inhibition of thrombin mediated fibrin clot for-
mation and the generation of thrombin by FXa. As men-
tioned earlier, AT also inhibits activated clotting factors
higher up in the intrinsic (FIXa, FXIa, FXIIa) and extrinsic
(FVIIa-tissue factor complex) pathways. It also inhibits a
series of other non-coagulant effects of these clotting factors,
including platelet activation, vascular cell signaling, prolif-
eration, cytokine production, etc. There are two paradoxes
concerning the effect of AT and its importance in the regu-
lation of clotting machinery: 1) it is a weak progressive
inhibitor of activated clotting factors, 2) it fails to inhibit
effectively fibrin-bound thrombin and FXa present in an
activation complex on the platelet surface.
As discussed in the previous section, interaction with hep-
arin, or its in vivo ‘‘substitute’’ HSPG, significantly accel-
erates the inhibitory action of AT and makes it a highly
effective inhibitor of thrombin, FXa and other active clotting
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Figure 1 Structural elements of antithrombin (AT) in its native (A) and latent (B) state based on the X-ray structure in the RCSB protein
data bank (pdb ID: 2b4x).
The b-sheets A, B and C are colored yellow, green and purple, respectively. Helical secondary structural elements are shown in orange,
except for helix D that is shown in black. Helix D plays a crucial role in heparin pentasaccharide binding. (In the case of serpins, conserved
helical structure elements are identified by capital letters.) The P3-P14 portion of the reactive center loop consisting of P1-P17 and P1’-P17’
residues is colored dark blue. The Arg393 (P1) residue is shown by a ball-and-stick representation. In the latent state, a substantial portion
of the reactive center loop is inserted into b-sheet A as an additional b-strand. The figures were prepared using Chimera software (Resource
for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, CA, USA) (19).
Figure 2 Schematic representation of the mechanism of activation and action of antithrombin (AT) on FXa.
(A) The native (circulating) form of AT, (B) the pentasaccharide-activated AT, (C) AT-factor Xa (FXa) complex; only epidermal growth
factor 2 (EGF 2) and serine protease domains of FXa are shown, (D) the acyl-enzyme complex in which FXa is covalently linked to AT.
For the A, B and C parts of the figure the X-ray coordinates wpdb IDs are 2b4x, 2gd4 (AT only) and 2gd4 (AT-FXa), respectivelyx deposited
in the protein data bank (20) were used. The construction of (D) was based on the structure of the a1-antitrypsin-elastase acyl-enzyme
complex (pdb ID: 2d26) (21). a1-antitrypsin was replaced by AT and elastase was substituted by FXa. Next, energy minimization of the
constructed complex was performed with Yasara software (Yasara Biosciences GmbH, Vienna, Austria) (www.yasara.org). b-sheets and
helices are shown in magenta and orange, respectively. Peptide sections that undergo remarkable conformational changes wP1-P15 section
of the reactive center loop (RCL), the third b-strand of b-sheet A (s3A) and helix D (hD)x are depicted in green. The Arg393 residue and
the pentasaccharide (PeS) are shown by ball-and-stick representations. The figures was prepared using Chimera software (19).
factors (5). HSPG is widely available on the vascular endo-
thelium and/or in the underlying subendothelial matrix and
tissues. Only a minor portion of HSPG contains the 3-O-
sulfated pentasaccharide unit required for the acceleration of
AT activity (25). This active HSPG (A-HSPG) species con-
stitutes 5% of the total HSPG associated with rat microvas-
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cular endothelial cells. Studies of its distribution in different
vessels (26, 27) suggest that A-HSPG present on the surface
of endothelial cells provides a basic level of activated AT
for anticoagulant activity, while the availability of a much
larger pool following endothelial damage and vessel wall
injury dramatically increases the anticoagulant potential of
AT. The relative importance of progressive AT activity or A-
HSPG induced activity in the physiological regulation of
blood coagulation is not clear. The fact that homozygous
mutations at the heparin binding site, which render AT una-
ble to bind GAGs, are compatible with life (see later for
details), as opposed to other homozygous AT deficiencies,
suggests the importance of progressive activity. On the other
hand, the severe thrombophilia seen in such patients under-
lines the importance of heparin/HSPG induced AT activation.
The association of active clotting factors with the surface
of activated platelets and with the fibrin clot significantly
modifies the inhibitory effect of AT or AT-heparin. When
present in the prothombinase complex on platelets or phos-
pholipid surfaces, FXa escapes the inhibition by AT (28–30).
Thrombin bound to fibrin or to fibrin degradation products
becomes refractive to inhibition by the AT-heparin complex.
Fibrin, heparin and thrombin form a ternary complex, in
which thrombin exosite 1 and exosite 2 are occupied by
fibrin and heparin, respectively (31). This prevents AT-asso-
ciated heparin from interacting with exosite 2 on fibrin-
bound thrombin, and the bridging action of heparin cannot
operate. It is of interest that FVIIa becomes sensitive to inhi-
bition by AT only when bound to tissue factor (16, 17). The
above findings suggest a double role for the AT and AT-A-
HSPG complex in the physiological regulation of blood
coagulation. It might control low-level thrombin formation
that occurs physiologically in the unperturbed circulation by
the inhibition of tissue factor-FVIIa complex, FXa and per-
haps other active clotting factors. AT might also exert a scav-
enger function by neutralizing FXa and thrombin that have
escaped from the clot and from the activation complex. The
latter mechanism could prevent the propagation of the clot
to areas away from the site of vascular injury.
In vivo, the AT-protease complex is rapidly eliminated
from the circulation by utilizing a common serpin-protease
complex clearance pathway. Binding to members of the low-
density lipoprotein receptor family, primarily to low density
lipoprotein-related protein which is an important receptor in
the liver, is the main pathway of the elimination of serpin-
protease complexes (5, 32).
Gene structure of antithrombin
The gene for human AT (SERPINC1) is located at the 1q23-
q25 position and contains seven exons producing a 1.4-kb
messenger RNA (mRNA), and six introns (33, 34). All the
exon/intron boundaries follow the GT-AG rule. Nine com-
plete and one partial Alu repeats were identified in introns
1, 2, 3B, 4 and 5. There is a highly polymorphic trinucleotide
repeat sequence in intron 4 which is useful for haplotype
analysis in studies of recurrent mutations and for linkage
analysis in families with thrombosis (35). Primer extension
analysis has mapped the AT transcriptional start site in liver
cells to a position 72 bp upstream of the ATG translation
initiator codon (36). A leader sequence of 32 amino acids is
encoded by exon 1 and the 5’ end of exon 2 (37). The hep-
arin binding site of AT is encoded by exon 2 and exon 3a.
The reactive site, located in the carboxy-terminal part of the
protein, is encoded by exon 6.
Epidemiology of antithrombin deficiency
The prevalence of inherited AT deficiency in the general
population is estimated to be between 1:2000 and 1:3000
(38). Most of the genetic defects result in type II (qualitative)
deficiencies (39). The prevalence of AT deficiency in
patients with venous thromboembolism (VTE) is much high-
er, between 1:20 and 1:200 (40). According to an Italian
study of symptomatic patients and relatives, type I mutations
(quantitative deficiencies) are more frequent than type II var-
iants (41).
In unselected patients with a history of VTE, the frequen-
cy of AT deficiency is 0.5%–1.1% (40, 42). In a cumulated
analysis of 1705 selected patients with VTE, the frequency
of AT deficiency was 2.4% (43). During a mean follow-up
time of 2.3 years the incidence of venous thrombosis was
high; being 12% in individuals with hereditary AT deficiency
in a small Italian cohort (44). For comparison, the incidence
of thrombosis in protein C (PC) and protein S (PS) deficien-
cy was 2.8% and 3.3%, respectively.
In the large prospective EPCOT study (European Prospec-
tive Cohort on Thrombophilia), the risk of first VTE in
asymptomatic AT, PC or PS deficient individuals and in indi-
viduals with Factor V Leiden mutation was analyzed
(ns575). During the 5.7 year of follow-up, 4.5% of these
individuals developed VTE, the annual incidence of first
VTE was the highest in those with AT deficiency (1.7%/
year) (45). Based on the prevalence data in the general pop-
ulation and in VTE patients, the relative risk of VTE in
patients with AT deficiency was estimated to be approx-
imately 25–50-fold (46). Since then, prospective and case-
control studies have calculated the same magnitude of VTE
risk conferred by AT deficiency in different ethnical groups
(47–49). Based on the results of these epidemiological stud-
ies, it can be concluded that the risk of VTE conferred by
hereditary AT deficiency is the highest among inherited
thrombophilias. However, the risk of VTE seems to vary
according to the subtypes of AT deficiency (see later).
AT deficiency also represents an increased risk for devel-
opment of PE in deep venous thrombosis (DVT), and an
increased risk for recurrence of VTE. In an Italian study of
patients with proximal DVT, the risk of pulmonary embolism
(PE) was 2.4-fold (95% CI: 1.61–3.63) in AT deficient
patients compared to individuals who developed DVT with-
out inherited thrombophilia (50). In AT deficiency, the annu-
al incidence of recurrent VTE was found to be 10% (95%
CI: 6.1%–15.4%) in a recently released Dutch study (51). In
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an Italian cohort, the adjusted hazard ratio for the recurrence
of VTE was 1.9 (95% CI: 1.0–3.9) (52).
Molecular genetic background of antithrombin
deficiency, genotype-phenotype correlations
The first report on AT deficiency was described by Egeberg
in 1965 (53). The first functional AT defect, AT Budapest,
was reported by Sas et al. in 1974 (54). Since then, a high
number of deficient patients have been identified, and the
molecular genetic background was clarified in a significant
number of cases. According to the recommendations of the
International Society on Thrombosis and Haemostasis, AT
deficiency is classified as type I (quantitative) and type II
(qualitative) deficiency (55). In type I deficiency, AT activity
and the antigen concentration are equally decreased, sug-
gesting defective synthesis or secretion of the protein. In type
II deficiency, the defect may involve the reactive site (type
II RS), the heparin-binding site (type II HBS) or it can exert
a pleiotropic effect (type II PE) (56). The inheritance of AT
deficiency, in general, is autosomal dominant. However, in
the case of type II HBS deficiency, it often shows incomplete
penetrance or an autosomal recessive pattern. The majority
of AT deficient patients are heterozygous for the defect with
typical AT activity values approximately 50%. Homozygo-
sity is incompatible with life, with the exception of type II
HBS variant (described later). The molecular genetic back-
ground of AT deficiency is heterogeneous. The mutations are
best summarized in the Antithrombin Mutation Database
(http://www1.imperial.ac.uk/medicine/about/divisions/depart-
mentofmedicine/experimentalmedicine/haematology/coag/-
antithrombin/) and in the database of human gene mutation
data (HGMD) (http://www.hgmd.cf.ac.uk) (Figure 3).
Almost 50% of the 215 different mutations that have been
reported in the HGMD are missense mutations. Small dele-
tions and insertions are also common, contributing 20% and
10%, respectively. Non-sense mutations and splicing site
mutations represent 8% and 5% of all reported causative
sequence variants, respectively. Whole or partial gene dele-
tions are relatively frequent (5%), while complex rearrange-
ments are rare.
Type I AT deficiencies are most commonly caused by
insertions or deletions leading to frameshift and premature
stop codon, or less commonly by non-sense mutations. These
mutations obviously explain the type I phenotype, primarily
a result of unstable mRNA transcripts and/or the presence of
truncated proteins. Large gene segment deletions also lead
to type I deficiency. By screening ‘‘mutation negative’’ AT
deficient cases using the multiplex ligation-dependent probe
amplification (MLPA) technique, several gross deletions
were identified. The breakpoints are often located within Alu
repeat elements (57). Amino acid changes caused by single
nucleotide substitutions within the coding region of SER-
PINC1 may also lead to type I deficiency. In this case, the
absence of mutant protein in the circulation is due to mis-
folding or a secretion defect (4).
The type II AT deficiencies are most commonly caused
by missense mutations. Among the mutations known to
involve the reactive site domain, two regions are preferred:
the hinge region (most frequently residues Ala382 and
Ala384) and around the reactive domain at residues Gly392
(AT Stockholm), Arg393 and Ser394 (58). Most of the mis-
sense mutations leading to type II HBS deficiency affect res-
idues Pro41 (AT Basel), Arg47 (AT Padua I), Leu99 (AT
Budapest 3) and Arg129. Practically all patients with AT
Budapest 3 (p.Leu99Phe) mutation described to date were of
South Eastern European origin, which may suggest a founder
effect (35, 59–61). Type II PE deficiency is caused by muta-
tions involving residues 402, 404–407 and 429. This region
is responsible for both the structural and functional integrity
of AT. These mutations lead to impaired function of the reac-
tive site and also to reduced secretion (58). A new pleiotropic
mutant (AT Murcia, p.K241E) has been described recently
in which altered glycosylation of the molecule led to
impaired heparin binding and thrombin inhibition (62). Some
of the missense mutations occurred in the mobile regions of
AT, mainly at the hinges of the reactive center loop, or in
the region involved in the shutter-like opening of the main
b-sheet of the molecule. The latter is required for insertion
of the reactive loop into the b-sheet. Even change in a single
amino acid in these sensitive regions can lead to conforma-
tional changes, loss of stability that facilitates the formation
of intermolecular linkages and lead to the formation of oligo-
mers or transformation to the latent conformation (4). The
secretion of these variants is also impaired which results in
a circulating deficiency.
Homozygous type I AT deficiency is not compatible with
life and heterozygous patients usually suffer severe throm-
bosis at a young age. The same stands for type II RS and
type II PE deficiencies. However, there is at least one notable
exception. The heterozygous p.Ala384Ser mutation (AT
Cambridge II) causes type II RS deficiency with a mild phe-
notype, and this mutation can also exist in homozygous form
(63, 64). Type II HBS deficiency confers a lower risk of
thrombosis compared with the other subtypes (65, 66).
Homozygous type II HBS patients usually survive, throm-
bosis may develop even earlier (frequently in childhood)
than in patients with heterozygous type I or other type II
deficiencies.
Symptoms of AT deficiency are DVT and/or PE which are
often recurrent. DVT not infrequently develops at unusual
sites, such as in the proximal extremities, and in mesenteric,
renal, portal, retinal and cerebral veins (67–70). Intracardial
atrial thrombosis has also been reported (71). The risk of
thrombosis conferred by AT deficiency to pregnant women
is significantly greater than in other deficiencies. The esti-
mated risk is 1:2.8 for women with type I deficiency, which
is approximately 350-times higher than the risk conferred by
pregnancy alone (72, 73).
In addition to venous thrombosis, occasionally, arterial
thrombosis has also been reported in patients with AT defi-
ciency (74, 75). AT Cambridge (p.A384S) mutation
increased the risk of myocardial infarction 5.66-fold as
reported by a Spanish study that enrolled 1224 patients and
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Figure 3 Distribution of causative mutations in the SERPINC1 gene according to the database of human gene mutation data (HGMD)
that have been published to date (www.hgmd.cf.ac.uk).
Nucleotide numbering is given relative to the first nucleic acid of the initiator ATG codon. Amino acids are numbered according to the
mature protein, where the first methionine is numbered –32.
1649 controls (76). In contrast, in a large cohort of relatives
of VTE patients with PC, PS or AT deficiency (ns468), the
risk of arterial thrombosis in those -55 year of age was
increased only in PC and PS deficient patients, while AT
deficiency was not associated with an increased risk (hazard
ratio 1.1, 95% CI: 0.1–10.9) (77). According to a recent
meta-analysis of studies involving children with arterial
ischemic stroke and cerebral venous sinus thrombosis, the
summary OR for the risk of arterial ischemic stroke in chil-
dren having AT deficiency was 3.29 (95% CI: 0.70–15.48),
while the OR for the risk of cerebral venous sinus thrombosis
was 18.41 (95% CI: 3.25–104.29) (78). These findings do
not support a significant contribution of AT deficiency to the
risk of atherothrombotic events.
Acquired antithrombin deficiency
In healthy full-term newborns, the concentration of AT is in
the range of 51%–75% of adult average values (79). Due to
severe immaturity of the liver, in preterm infants AT con-
centrations can be much lower than in full terms infants (80).
AT concentrations reach adult ranges by the age of 1 year
(81). Production of AT is reduced in liver disease with
impaired hepatic function. In patients with nephrotic syn-
drome or other diseases associated with renal or enteral pro-
tein loss, the low AT concentration is due to increased
elimination. Low concentrations of AT as a result of con-
sumption are found in patients with sepsis, disseminated
intravascular coagulation, large thrombus, thrombotic micro-
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Figure 4 Measurement principle of chromogenic antithrombin
assays.
Both anti-thrombin and anti-FXa heparin cofactor assays are dem-
onstrated. AT, antithrombin; AT*, antithrombin activated by hepa-
rin; FXa, activated factor X; R, the peptide part of chomogenic
thrombin or FXa substrates; pNA, para-nitro aniline. In the last line,
the oligopeptide components of a thrombin (thr) substrate (S-2238)
and a FXa substrate (S-2772) are shown.
Table 1 Laboratory diagnosis and classification of antithrombin
(AT) deficiencies.
Subtypes of AT Heparin cofactor Progressive AT antigen
deficiencies AT assay AT assay assay
Type I x x x
Type II RS x x n
Type II HBS x n n
Type II PE x x n or subnormal
RS, reactive site; HBS, heparin binding site; PE, pleiotrop;
n, normal.
angiopathy, acute hemolytic transfusion reactions and malig-
nancies (82). There are two notable examples of drug-
induced AT deficiency. Long-term therapy with unfraction-
ated heparin is a common cause of moderate AT consump-
tion, which is probably the result of greatly enhanced
formation of thrombin-AT complex in plasma. Therapy with
L-asparaginase leads to intracellular retention of AT within
the endoplasmic reticulum, perhaps due to interference with
folding of the molecule and with glycosylation of the protein
(83, 84). Interestingly, co-administration of dexaamethasone
with L-asparaginase increased the concentration of AT and
reduced the risk of thrombosis. The effect of dexamethasone
is possibly due to induced expression of heat shock proteins
and endoplasmic reticulum-associated chaperons which
prevent the conformational effect of L-asparaginase (85).
Laboratory diagnosis of antithrombin deficiency
A first-line test for the diagnosis of AT deficiency should
detect all deficiencies, i.e., AT deficiencies due to decreased
AT concentration as well as to a defective molecule. There-
fore, the first line test should be a functional assay. The orig-
inal clotting methods where the inhibition of thrombin by
diluted native serum or defibrinated plasma was measured
by fibrinogen clotting are impractical and inaccurate and not
in use any longer. With the modern chromogenic (amidoly-
tic) assays, the inhibition of thrombin or FXa activity by AT
is measured using thrombin/FXa specific tri, or tetra-peptide
substrates which show sequential similarity to the P1-P3 or
P1-P4 sequences of the natural substrates of these enzymes
(Figure 4) (86, 87). The peptides conform to the active site
of the respective active clotting factor and a para-nitroanaline
(pNA) group is attached to their C-terminal end. Thrombin
or FXa rapidly release the pNA group from their peptide
substrate. Free pNA, as opposed to the peptide-bound form,
has strong light absorption at 405 nm and its release can be
easily monitored spectrophotometrically. The assays can be
performed in the presence of heparin (heparin cofactor activ-
ity) or without heparin (progressive activity). In the former
assays, the inhibition of active clotting factors is very quick,
while in the latter cases more time is required for ATII to
exert its inhibitory action. As only the heparin cofactor activ-
ity is decreased in all subtypes of AT deficiency (Table 1),
the assay measuring this activity is the generally accepted
first line test for the diagnosis of deficiency. Unfortunately,
as external quality control exercises reveal, the improper
practice of using only an antigenic AT assay, which detects
-50% of AT deficiencies, still exists in a few laboratories.
Figure 4 demonstrates the assay principle of amidolytic
AT assays. Heparin binds to AT making it highly reactive
with thrombin and FXa (activated AT; AT*). Thrombin or
FXa is added in excess of AT and a part of it becomes rap-
idly complexed with heparin-AT*, in the complex AT activ-
ity is abrogated. The extent of thrombin/FXa inhibition
depends on plasma AT activity, and the residual free throm-
bin or FXa is inversely related to AT activity. The amount
of free thrombin or FXa is measured using a chromogenic
substrate described above. The increase in absorbance at
405 nm can be measured using a kinetic or end-point method
(the former is preferred), and the change of absorbance is
converted to AT activity using a calibration curve. Reference
plasma of known AT activity is used to construct the cali-
bration curve. A WHO international standard (2nd Interna-
tional Standard Antithrombin, Plasma, NIBSC code: 93/768)
with an assigned potency of 0.85 International Units (IU) is
available from the National Institute for Biological Standards
and Control (NIBSC; Potters Bar, UK). This international
plasma standard should be used by companies for the cali-
bration of their reference plasma and this information should
be stated on the application sheet.
The chromogenic heparin cofactor AT assay has good
reproducibility. Laboratories equipped with automated labo-
ratory analyzers or coagulometer should aim for within-batch
precision CVF2%, and for within-laboratory reproducibility
(total error) CVF5%. According to a previous report based
on the quality assessment program for thrombophilia screen-
ing by the ECAT Foundation which included 136 laborato-
ries during the time period 1996–2001, the median long-term
within-laboratory analytical CV was 7.6% with a 95% CI of
3.6–35.5 (88). These values suggest that for many labora-
tories, there is much work needed to improve the quality
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performance of AT assays. Joining an international accred-
ited external quality assessment program is highly recom-
mended for laboratories routinely performing AT
measurements.
Human thrombin was used in previous thrombin inhibition
assays. Human thrombin also reacted with heparin cofactor
II and made the assay relatively insensitive for the detection
of AT deficiency (89, 90). In most commercial kits, human
thrombin has been replaced by bovine thrombin which shows
minimal reaction with heparin cofactor II. FXa does not react
with heparin cofactor II at all. Heparin cofactor AT assays
based on bovine thrombin and FXa inhibition seem to func-
tion equally well, the sensitivity of both assays is close to
100%. As the reactive site of thrombin and FXa differs
somewhat, one would expect that AT deficiencies caused by
certain mutations around the reactive site are detected by the
two types of assays with different sensitivity. Indeed, the
Ala384Ser mutation (AT Cambridge II) which is a relatively
prevalent variant in the general population, is not detected
by the anti-FXa assay, but anti-thrombin activity is mildly,
but significantly, reduced (63, 64). However, this mutation
causes only a relatively mild thrombophilia, and even elderly
homozygous individuals might lack the history of VTE. In
contrast, according to our experience with a high number of
AT Budapest 3 mutants, the anti-Xa assay is significantly
more sensitive in detecting this type II HBS deficiency com-
pared with the assay based on thrombin inhibition.
Progressive AT assays are based on the same principle as
heparin cofactor assays, but are performed in the absence of
heparin on less diluted plasma samples. In addition, the incu-
bation time is prolonged significantly. Unfortunately, the
application sheets for the commercial AT activity assays do
not provide a description on how to use the test kit as a
progressive assay, the appropriate conditions need to be
established by the user. These conditions may vary among
commercial kits, and the user needs to experiment. As a start-
ing point, 10-fold diluted plasma and a 15-min incubation
time is recommended. Although this test is essential for the
diagnosis of type II HBS deficiency (Table 1), for the reasons
mentioned above, the progressive assay is very much under
utilized in the diagnosis and classification of AT deficiencies
(91). As discussed earlier, differentiation between heterozy-
gous type II HBS deficiency causing mild thrombophilia and
other type of functional defects causing a severe phenotype
is of clinical relevance. In certain, clinical set-ups this might
influence the decision concerning anticoagulant therapy. Dis-
tinguishing between homozygous type II HBS deficient
patients who have a very severe phenotype, and heterozy-
gotes is also of clinical relevance.
Measurement of AT antigen concentrations is required for
the classification of AT deficiencies. Traditional electro-
immunodiffusion and radial-immunodiffusion techniques are
too time consuming, imprecise and their use is no longer
recommended. At present, latex-enhanced immuno nephe-
lometry is the most frequently used method for measurement
of AT antigen concentrations (92), and commercial kits for
this purpose are available.
It is rather surprising that no reference interval determined
according to guideline (C28-A3) from the Clinical and Lab-
oratory Standards Institute (CLSI; Wayne, PA, USA) is avail-
able for AT activity and antigen. A number of different
‘‘normal’’ ranges, varying within a narrow interval have
been reported in the literature and are available in manufac-
turer’s application sheets. Accepting 80% of the average nor-
mal (0.8 IU/mL) as the lower limit of reference interval for
AT activity seems to be an acceptable compromise, and most
laboratories use this value. The upper limit of the reference
interval does not have any clinical relevance. AT antigen
concentrations can be expressed as mass concentration
(mg/L), although there are a rather wide variety of ‘‘normal’’
ranges for mass concentration. In addition, values for mass
concentration are difficult to compare to AT activity values.
For this reason most laboratories use the same principle and
the same reference interval for AT antigen as for AT activity.
It should be noted that by definition, 2.5% of the values
obtained with normal, non-deficient samples are below the
lower limit of the reference interval, and values between 70%
and 80% should be interpreted with extreme caution.
Platelet poor citrated plasma is used for both activity and
antigen measurements and can be stored at –208C for up to
4 months. Measurement of AT activity and concentration is
not recommended within 3 months of an acute event. During
this period, if values are within the reference interval, the
exclusion of AT deficiency is possible, but the diagnosis of
AT deficiency cannot be confirmed. In a number of cases,
AT determination is requested for patients who are on anti-
coagulant therapy. Oral anticoagulant therapy with vitamin
K antagonists, such as warfarin or acenocoumarol might
increase the level of AT (93–98), while administration of
unfractionated heparin decreases the concentration of AT
(58, 94, 97, 99). Low molecular weight heparins do not have
such an effect (100). For these reasons, we do not recom-
mend diagnosing AT deficiency in patients who are under-
going unfractionated heparin therapy. Also, we do not
recommend attempting to exclude AT deficiency during oral
anticoagulant therapy. In our experience switching from oral
anticoagulant therapy to low molecular heparin for 10 days
prior to blood collection is a good compromise which allows
the measurement of valid AT values. The algorithm used in
the authors’ laboratory for the diagnosis and classification of
AT deficiency is demonstrated in Figure 5. If heparin cofac-
tor AT activity is -80% we carefully look for and exclude
acquired AT deficiencies, such as liver disease, renal or
enteral protein loss, consumption coagulopathy, unfraction-
ated heparin treatment or therapy with l-asparaginase. To
establish the diagnosis, repeated tests are required from dif-
ferent blood samples collected from the same person. If fea-
sible, we recommend a time interval of at least 3 weeks
between the two blood collections. If the heparin cofactor
activity is repeatedly equal to or -70% and acquired causes
have been excluded, the laboratory diagnosis of inherited AT
deficiency can be established. Between 70% and 80% of AT
activity, it is highly recommended to confirm the diagnosis
by molecular genetic testing. Once AT deficiency is diag-
nosed, the next step is its classification, which occurs in two
steps. Plasma AT antigen concentrations are measured to dif-
ferentiate between type I and type II deficiency. Decreased
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Figure 5 Laboratory diagnosis and classification of antithrombin
(AT) deficiency.
Assays are shown in rectangles, diagnoses in italics are underlined.
As stated in the text, we do not recommend diagnosing AT defi-
ciency in patients receiving therapy with unfractionated heparin, and
do not recommend excluding AT deficiency during oral anticoag-
ulant therapy.
AT antigen implies type I deficiency, while AT antigen in
the normal range indicates type II deficiency. Finally, it is
clinically important to distinguish II HBS subtype from other
type II variants by performing a progressive activity assay.
As opposed to other type II subtypes, HBS variants have
normal progressive activity. Table 1 summarizes the results
of diagnostic and classification tests in different subtypes of
AT deficiency.
Concluding remarks
AT is a slow progressive inhibitor of active clotting factors,
particularly thrombin and factor Xa (FXa). Glycosaminogly-
cans with a 3-O-sulfated pentasaccharide unit, like heparin
or heparan sulfate, bind to AT with high affinity and greatly
accelerate the reaction with active clotting factors. Even in
the presence of heparin/heparan sulfate, AT poorly inhibits
FXa in activation complex and fibrin-bound thrombin. It
might control low level thrombin formation that occurs phys-
iologically, and could also exert a scavenger function by neu-
tralizing FXa and thrombin that have escaped from the clot
and from the activation complex. In general, inherited AT
deficiency causes severe thrombophilia. However, the phe-
notypic appearance varies with different subtypes. Homo-
zygous type I AT deficiency caused by decreased synthesis
or secretion is incompatible with life. In the heterozygous
form, it is frequently accompanied by DVT, not infrequently
of unusual localization, or PE after the second decade of life.
Functional defects (type II AT deficiencies) caused by mis-
sense mutations are classified according to the site that is
affected by the mutation as reactive site (RS), heparin bind-
ing site (HBS) AT deficiencies or multiple site defect caused
by mutations with pleiotropic effects (PE). Type II HBS sub-
type is less severe than other AT deficiencies. In the heter-
ozygous form it presents with only mild thrombophilia, and
homozygotes also survive, although usually with very early
thrombotic complications.
The diagnosis of inherited AT deficiency is important for
establishing the risk of recurrent thrombotic events. The
diagnosis might influence the clinical decision concerning
the duration of anticoagulant therapy. The diagnosis is estab-
lished by laboratory tests, although the exclusion of acquired
deficiency requires careful clinical attention. The first line
test is a functional chromogenic heparin cofactor assay,
which measures the inhibition of thrombin or the inhibition
of FXa in the presence of heparin. Both anti-thrombin and
anti-FXa assays perform well and, with very few exceptions,
detect all subtypes of AT deficiency. The reference interval
is quite narrow and in most cases the range of 80%–120%
of average normal is accepted. Measurement of AT antigen
concentrations allows differentiation between type I and type
II AT deficiencies, while progressive AT activity assays are
required to make the clinically important distinction between
type II HBS and other type II subtypes. Increased utilization
of a progressive activity assay is desirable. The diagnosis
might be confirmed by molecular genetic testing, which is
important in the case of activities in the range of 70%–80%.
Acknowledgements
This work was supported by a grant from the Hungarian National
Research Fund (OTKA K78386).
Conflict of interest statement
Author’s conflict of interest disclosure: The authors stated that
there are no conflicts of interest regarding the publication of this
article.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
References
1. Abildgaard U. Antithrombin – early prophecies and present chal-
lenges. Thromb Haemost 2007;98:97–104.
2. Mosesson MW. Update on antithrombin I (fibrin). Thromb Hae-
most 2007;98:105–8.
3. Rau JC, Beaulieu LM, Huntington JA, Church FC. Serpins in
thrombosis, hemostasis and fibrinolysis. J Thromb Haemost
2007;5 Suppl 1:102–15.
4. Hernandez-Espinosa D, Ordonez A, Vicente V, Corral J. Factors
with conformational effects on haemostatic serpins: implications
in thrombosis. Thromb Haemost 2007;98:557–63.
S76 Muszbek et al.: Antithrombin deficiency
Article in press - uncorrected proof
5. Bock SC. Antithrombin III and heparin cofactor II. In: Colman
RW, Clowes AW, Goldhaber SZ, Marder VJ, George JN, edi-
tors. Hemostasis and Thrombosis, Vol. Philadelphia: Lippincott,
2006:235–48.
6. Carrell RW, Stein PE, Fermi G, Wardell MR. Biological impli-
cations of a 3-A structure of dimeric antithrombin. Structure
1994;2:257–70.
7. Schreuder HA, de Boer B, Dijkema R, Mulders J, Theunissen
HJ, Grootenhuis PD, et al. The intact and cleaved human anti-
thrombin III complex as a model for serpin-proteinase inter-
actions. Nat Struct Biol 1994;1:48–54.
8. Whisstock JC, Pike RN, Jin L, Skinner R, Pei XY, Carrell RW,
et al. Conformational changes in serpins: II. The mechanism of
activation of antithrombin by heparindagger. J Mol Biol 2000;
301:1287–305.
9. Huntington JA, Gettins PG. Conformational conversion of anti-
thrombin to a fully activated substrate of factor Xa without need
for heparin. Biochemistry 1998;37:3272–7.
10. Whisstock JC, Bottomley SP. Molecular gymnastics: serpin
structure, folding and misfolding. Curr Opin Struct Biol
2006;16:761–8.
11. Johnson DJ, Li W, Adams TE, Huntington JA. Antithrombin-
S195A factor Xa-heparin structure reveals the allosteric mech-
anism of antithrombin activation. EMBO J 2006;25:2029–37.
12. Langdown J, Belzar KJ, Savory WJ, Baglin TP, Huntington JA.
The critical role of hinge-region expulsion in the induced-fit
heparin binding mechanism of antithrombin. J Mol Biol 2009;
386:1278–89.
13. Johnson DJ, Langdown J, Huntington JA. Molecular basis of
factor IXa recognition by heparin-activated antithrombin
revealed by a 1.7-A structure of the ternary complex. Proc Natl
Acad Sci USA 2010;107:645–50.
14. Huntington JA. Shape-shifting serpins – advantages of a mobile
mechanism. Trends Biochem Sci 2006;31:427–35.
15. Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB,
Gettins PG, et al. The serpins are an expanding superfamily of
structurally similar but functionally diverse proteins. Evolution,
mechanism of inhibition, novel functions, and a revised nomen-
clature. J Biol Chem 2001;276:33293–6.
16. Rao LV, Rapaport SI, Hoang AD. Binding of factor VIIa to
tissue factor permits rapid antithrombin III/heparin inhibition
of factor VIIa. Blood 1993;81:2600–7.
17. Lawson JH, Butenas S, Ribarik N, Mann KG. Complex-
dependent inhibition of factor VIIa by antithrombin III and hep-
arin. J Biol Chem 1993;268:767–70.
18. Broze GJ Jr, Likert K, Higuchi D. Inhibition of factor VIIa/
tissue factor by antithrombin III and tissue factor pathway
inhibitor. Blood 1993;82:1679–81.
19. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt
DM, Meng EC, et al. UCSF Chimera – a visualization system
for exploratory research and analysis. J Comput Chem 2004;
25:1605–12.
20. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weis-
sig H, et al. The Protein Data Bank (www.rcsb.org). Nucleic
Acids Research 2000;28:235–42.
21. Dementiev A, Dobo J, Gettins PG. Active site distortion is
sufficient for proteinase inhibition by serpins: structure of the
covalent complex of alpha1-proteinase inhibitor with porcine
pancreatic elastase. J Biol Chem 2006;281:3452–7.
22. Dementiev A, Petitou M, Herbert JM, Gettins PG. The ternary
complex of antithrombin-anhydrothrombin-heparin reveals the
basis of inhibitor specificity. Nat Struct Mol Biol 2004;11:
863–7.
23. Li W, Johnson DJ, Esmon CT, Huntington JA. Structure of the
antithrombin-thrombin-heparin ternary complex reveals the
antithrombotic mechanism of heparin. Nat Struct Mol Biol
2004;11:857–62.
24. Bjork I, Jackson CM, Jornvall H, Lavine KK, Nordling K, Sals-
giver WJ. The active site of antithrombin. Release of the same
proteolytically cleaved form of the inhibitor from complexes
with factor IXa, factor Xa, and thrombin. J Biol Chem
1982;257:2406–11.
25. Kojima T, Leone CW, Marchildon GA, Marcum JA, Rosenberg
RD. Isolation and characterization of heparan sulfate proteo-
glycans produced by cloned rat microvascular endothelial cells.
J Biol Chem 1992;267:4859–69.
26. de Agostini AI, Watkins SC, Slayter HS, Youssoufian H,
Rosenberg RD. Localization of anticoagulantly active heparan
sulfate proteoglycans in vascular endothelium: antithrombin
binding on cultured endothelial cells and perfused rat aorta. J
Cell Biol 1990;111:1293–304.
27. Faulk WP, Labarrere CA. Modulation of vascular antithrombin
III in human cardiac allografts. Haemostasis 1993;23 Suppl
1:194–201.
28. Marciniak E. Factor-Xa inactivation by antithrombin. 3. Evi-
dence for biological stabilization of factor Xa by factor V-phos-
pholipid complex. Br J Haematol 1973;24:391–400.
29. Teitel JM, Rosenberg RD. Protection of factor Xa from neu-
tralization by the heparin-antithrombin complex. J Clin Invest
1983;71:1383–91.
30. Lindhout T, Baruch D, Schoen P, Franssen J, Hemker HC.
Thrombin generation and inactivation in the presence of anti-
thrombin III and heparin. Biochemistry 1986;25:5962–9.
31. Becker DL, Fredenburgh JC, Stafford AR, Weitz JI. Exosites 1
and 2 are essential for protection of fibrin-bound thrombin from
heparin-catalyzed inhibition by antithrombin and heparin cofac-
tor II. J Biol Chem 1999;274:6226–33.
32. Kounnas MZ, Church FC, Argraves WS, Strickland DK. Cel-
lular internalization and degradation of antithrombin III-
thrombin, heparin cofactor II-thrombin, and alpha 1-anti-
trypsin-trypsin complexes is mediated by the low density
lipoprotein receptor-related protein. J Biol Chem 1996;271:
6523–9.
33. Olds RJ, Lane DA, Chowdhury V, De Stefano V, Leone G,
Thein SL. Complete nucleotide sequence of the antithrombin
gene: evidence for homologous recombination causing throm-
bophilia. Biochemistry 1993;32:4216–24.
34. Bock SC, Harris JF, Balazs I, Trent JM. Assignment of the
human antithrombin III structural gene to chromosome 1q23-
25. Cytogenet Cell Genet 1985;39:67–9.
35. Olds RJ, Lane DA, Chowdhury V, Sas G, Pabinger I, Auberger
K, et al. (ATT) Trinucleotide repeats in the antithrombin gene
and their use in determining the origin of repeated mutations.
Hum Mutat 1994;4:31–41.
36. Prochownik EV, Orkin SH. In vivo transcription of a human
antithrombin III ‘‘minigene’’. J Biol Chem 1984;259:15386–
92.
37. Aiach M, Gandrille S, Emmerich J. A review of mutations
causing deficiencies of antithrombin, protein C and protein S.
Thromb Haemost 1995;74:81–9.
38. Tait RC, Walker ID, Perry DJ, Islam SI, Daly ME, McCall F,
et al. Prevalence of antithrombin deficiency in the healthy pop-
ulation. Br J Haematol 1994;87:106–12.
39. McColl M, Tait RC, Walker ID, Perry DJ, McCall F, Conkie
JA. Low thrombosis rate seen in blood donors and their rela-
tives with inherited deficiencies of antithrombin and protein C:
correlation with type of defect, family history, and absence of
Muszbek et al.: Antithrombin deficiency S77
Article in press - uncorrected proof
the factor V Leiden mutation. Blood Coagul Fibrinolysis
1996;7:689–94.
40. Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J. Labora-
tory evaluation and clinical characteristics of 2,132 consecutive
unselected patients with venous thromboembolism – results of
the Spanish Multicentric Study on Thrombophilia (EMET-
Study). Thromb Haemost 1997;77:444–51.
41. Martinelli I, Mannucci PM, De Stefano V, Taioli E, Rossi V,
Crosti F, et al. Different risks of thrombosis in four coagulation
defects associated with inherited thrombophilia: a study of 150
families. Blood 1998;92:2353–8.
42. Heijboer H, Brandjes DP, Buller HR, Sturk A, ten Cate JW.
Deficiencies of coagulation-inhibiting and fibrinolytic proteins
in outpatients with deep-vein thrombosis. N Engl J Med
1990;323:1512–6.
43. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombo-
philia: pathogenesis, clinical syndromes, and management.
Blood 1996;87:3531–44.
44. Finazzi G, Barbui T. Different incidence of venous thrombosis
in patients with inherited deficiencies of antithrombin III, pro-
tein C and protein S. Thromb Haemost 1994;71:15–8.
45. Vossen CY, Conard J, Fontcuberta J, Makris M, van der Meer
FJ, Pabinger I, et al. Risk of a first venous thrombotic event in
carriers of a familial thrombophilic defect. The European Pro-
spective Cohort on Thrombophilia (EPCOT). J Thromb Hae-
most 2005;3:459–64.
46. Rosendaal FR. Risk factors for venous thrombotic disease.
Thromb Haemost 1999;82:610–9.
47. Sakata T, Okamoto A, Mannami T, Matsuo H, Miyata T. Pro-
tein C and antithrombin deficiency are important risk factors
for deep vein thrombosis in Japanese. J Thromb Haemost
2004;2:528–30.
48. Lijfering WM, Brouwer JL, Veeger NJ, Bank I, Coppens M,
Middeldorp S, et al. Selective testing for thrombophilia in
patients with first venous thrombosis: results from a retrospec-
tive family cohort study on absolute thrombotic risk for cur-
rently known thrombophilic defects in 2479 relatives. Blood
2009;113:5314–22.
49. Brouwer JL, Veeger NJ, Kluin-Nelemans HC, van der Meer J.
The pathogenesis of venous thromboembolism: evidence for
multiple interrelated causes. Ann Intern Med 2006;145:807–15.
50. Rossi E, Za T, Ciminello A, Leone G, De Stefano V. The risk
of symptomatic pulmonary embolism due to proximal deep
venous thrombosis differs in patients with different types of
inherited thrombophilia. Thromb Haemost 2008;99:1030–4.
51. Brouwer JL, Lijfering WM, Ten Kate MK, Kluin-Nelemans
HC, Veeger NJ, van der Meer J. High long-term absolute risk
of recurrent venous thromboembolism in patients with heredi-
tary deficiencies of protein S, protein C or antithrombin.
Thromb Haemost 2009;101:93–9.
52. De Stefano V, Simioni P, Rossi E, Tormene D, Za T, Pagnan
A, et al. The risk of recurrent venous thromboembolism in
patients with inherited deficiency of natural anticoagulants anti-
thrombin, protein C and protein S. Haematologica 2006;91:
695–8.
53. Egeberg O. Inherited antithrombin deficiency causing throm-
bophilia. Thromb Diath Haemorrh 1965;13:516–30.
54. Sas G, Blasko G, Banhegyi D, Jako J, Palos LA. Abnormal
antithrombin III (antithrombin III ‘‘Budapest’’) as a cause of a
familial thrombophilia. Thromb Diath Haemorrh 1974;32:
105–15.
55. Lane DA, Bayston T, Olds RJ, Fitches AC, Cooper DN, Millar
DS, et al. Antithrombin mutation database: 2nd (1997) update.
For the Plasma Coagulation Inhibitors Subcommittee of the
Scientific and Standardization Committee of the International
Society on Thrombosis and Haemostasis. Thromb Haemost
1997;77:197–211.
56. Lane DA, Olds RJ, Conard J, Boisclair M, Bock SC, Hultin M,
et al. Pleiotropic effects of antithrombin strand 1C substitution
mutations. J Clin Invest 1992;90:2422–33.
57. Picard V, Chen JM, Tardy B, Aillaud MF, Boiteux-Vergnes C,
Dreyfus M, et al. Detection and characterisation of large SER-
PINC1 deletions in type I inherited antithrombin deficiency.
Hum Genet 2010;127:45–53.
58. Patnaik MM, Moll S. Inherited antithrombin deficiency: a
review. Haemophilia 2008;14:1229–39.
59. Kuhle S, Lane DA, Jochmanns K, Male C, Quehenberger P,
Lechner K, et al. Homozygous antithrombin deficiency type II
(99 Leu to Phe mutation) and childhood thromboembolism.
Thromb Haemost 2001;86:1007–11.
60. Olds RJ, Lane DA, Boisclair M, Sas G, Bock SC, Thein SL.
Antithrombin Budapest 3. An antithrombin variant with
reduced heparin affinity resulting from the substitution L99F.
FEBS Lett 1992;300:241–6.
61. Sas G, Peto I, Banhegyi D, Blasko G, Domjan G. Heterogeneity
of the ‘‘classical’’ antithrombin III deficiency. Thromb Hae-
most 1980;43:133–6.
62. Martinez-Martinez I, Ordonez A, Navarro-Fernandez J, Perez-
Lara A, Gutierrez-Gallego R, Giraldo R, et al. Antithrombin
Murcia (K241E) causing antithrombin deficiency: a role for
altered glycosylation. Haematologica 2010;95:1358–65.
63. Perry DJ, Daly ME, Tait RC, Walker ID, Brown K, Beauchamp
NJ, et al. Antithrombin cambridge II (Ala384Ser): clinical,
functional and haplotype analysis of 18 families. Thromb Hae-
most 1998;79:249–53.
64. Corral J, Hernandez-Espinosa D, Soria JM, Gonzalez-Conejero
R, Ordonez A, Gonzalez-Porras JR, et al. Antithrombin Cam-
bridge II (A384S): an underestimated genetic risk factor for
venous thrombosis. Blood 2007;109:4258–63.
65. Finazzi G, Caccia R, Barbui T. Different prevalence of throm-
boembolism in the subtypes of congenital antithrombin III defi-
ciency: review of 404 cases. Thromb Haemost 1987;58:1094.
66. Girolami A, Lazzaro AR, Simioni P. The relationship between
defective heparin cofactor activities and thrombotic phenomena
in AT III abnormalities. Thromb Haemost 1988;59:121.
67. Harmanci O, Ersoy O, Gurgey A, Buyukasik Y, Gedikoglu G,
Balkanci F, et al. The etiologic distribution of thrombophilic
factors in chronic portal vein thrombosis. J Clin Gastroenterol
2007;41:521–7.
68. Ates O. The deficiencies of protein C, protein S and antithrom-
bin III in patients with retinal vein occlusion: a Turkish sample.
Clin Lab Haematol 2006;28:391–2.
69. Calcaterra D, Martin JT, Ferneini AM, De Natale RW. Acute
mesenteric and aortic thrombosis associated with antithrombin
deficiency: a rare occurrence. Ann Vasc Surg 2010;24:415
e5–7.
70. Shibahara K, Tatsuta K, Orita H, Yonemura T, Kohno H. Supe-
rior mesenteric and portal vein thrombosis caused by congenital
antithrombin III deficiency: report of a case. Surg Today 2007;
37:308–10.
71. Santangeli P, Sestito A. Acute left atrial thrombosis during anti-
coagulant therapy in a patient with antithrombin deficiency.
Acta Cardiol 2008;63:635–7.
72. McColl MD, Ramsay JE, Tait RC, Walker ID, McCall F,
Conkie JA, et al. Risk factors for pregnancy associated venous
thromboembolism. Thromb Haemost 1997;78:1183–8.
73. Sabadell J, Casellas M, Alijotas-Reig J, Arellano-Rodrigo E,
Cabero L. Inherited antithrombin deficiency and pregnancy:
S78 Muszbek et al.: Antithrombin deficiency
Article in press - uncorrected proof
maternal and fetal outcomes. Eur J Obstet Gynecol Reprod Biol
2010;149:47–51.
74. Tu CM, Hsueg CH, Chu KM, Cheng SM, Tsao TP. Simulta-
neous thromboses of double coronary arteries in a young male
with antithrombin III deficiency. Am J Emerg Med 2009;
27:1169 e3–6.
75. Peovska I, Maksimovic J, Kalpak O, Pejkov H, Bosevski M.
Recurrent myocardial infarction in a young football player with
antithrombin III deficiency. Cardiol J 2008;15:463–6.
76. Roldan V, Ordonez A, Marin F, Zorio E, Soria JM, Minano A,
et al. Antithrombin Cambridge II (A384S) supports a role for
antithrombin deficiency in arterial thrombosis. Thromb Hae-
most 2009;101:483–6.
77. Mahmoodi BK, Brouwer JL, Veeger NJ, van der Meer J. Hered-
itary deficiency of protein C or protein S confers increased risk
of arterial thromboembolic events at a young age: results from
a large family cohort study. Circulation 2008;118:1659–67.
78. Trenor CC 3rd, Michelson AD. Thrombophilia and pediatric
stroke. Circulation 2010;121:1795–7.
79. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollef-
sen DM, et al. Development of the human coagulation system
in the full-term infant. Blood 1987;70:165–72.
80. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollef-
sen DM, et al. Development of the human coagulation system
in the healthy premature infant. Blood 1988;72:1651–7.
81. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell
L. Maturation of the hemostatic system during childhood.
Blood 1992;80:1998–2005.
82. Maclean PS, Tait RC. Hereditary and acquired antithrombin
deficiency: epidemiology, pathogenesis and treatment options.
Drugs 2007;67:1429–40.
83. Bushman JE, Palmieri D, Whinna HC, Church FC. Insight into
the mechanism of asparaginase-induced depletion of antithrom-
bin III in treatment of childhood acute lymphoblastic leukemia.
Leuk Res 2000;24:559–65.
84. Hernandez-Espinosa D, Minano A, Martinez C, Perez-Ceballos
E, Heras I, Fuster JL, et al. L-asparaginase-induced antithrom-
bin type I deficiency: implications for conformational diseases.
Am J Pathol 2006;169:142–53.
85. Hernandez-Espinosa D, Minano A, Ordonez A, Mota R, Mar-
tinez-Martinez I, Vicente V, Corral J. Dexamethasone induces
a heat-stress response that ameliorates the conformational con-
sequences on antithrombin of L-asparaginase treatment. J
Thromb Haemost 2009;7:1128–33.
86. Abildgaard U, Lie M, Odegard OR. Antithrombin (heparin
cofactor) assay with ‘‘new’’ chromogenic substrates (S-2238
and Chromozym TH). Thromb Res 1977;11:549–53.
87. Odegard OR, Lie M, Abildgaard U. Antifactor Xa activity
measured with amidolytic methods. Haemostasis 1976;5:
265–75.
88. Meijer P, Kluft C, Haverkate F, De Maat MP. The long-term
within- and between-laboratory variability for assay of anti-
thrombin, and proteins C and S: results derived from the exter-
nal quality assessment program for thrombophilia screening
of the ECAT Foundation. J Thromb Haemost 2003;1:748–53.
89. Demers C, Henderson P, Blajchman MA, Wells MJ, Mitchell
L, Johnston M, et al. An antithrombin III assay based on fac-
tor Xa inhibition provides a more reliable test to identify con-
genital antithrombin III deficiency than an assay based on
thrombin inhibition. Thromb Haemost 1993;69:231–5.
90. Conard J, Bara L, Horellou MH, Samama MM. Bovine or
human thrombin in amidolytic at III assays. Influence of hep-
arin cofactor II. Thromb Res 1986;41:873–8.
91. Rossi E, Chiusolo P, Za T, Marietti S, Ciminello A, Leone G,
et al. Report of a novel kindred with antithrombin heparin-
binding site variant (47 Arg to His): demand for an automated
progressive antithrombin assay to detect molecular variants
with low thrombotic risk. Thromb Haemost 2007;98:695–7.
92. Parvez Z, Fareed J, Messmore HL, Moncada R. Laser neph-
elometric quantitation of antithrombin-III (AT-III) develop-
ment of a new assay. Thromb Res 1981;24:367–77.
93. Von Kaulla E, Von Kaulla KN. Antithrombin 3 and diseases.
Am J Clin Pathol 1967;48:69–80.
94. Marciniak E, Gockerman JP. Heparin-induced decrease in cir-
culating antithrombin-III. Lancet 1977;ii:581–4.
95. Conard J. Inhibitors of blood coagulation. In: Thompson JM,
editor. Blood Coagulation and Haemostasis, Vol. 2nd ed.
Edinburgh: Churchill Livingstone, 1980:200–21.
96. Laffan MaM R. Investigation of a thrombotic tendency. In:
Lewis SM, Bain BJ, Bates I, editors. Practical Haematology,
Vol. 10th ed. Philadelphia: Churchill Livingstone, 2006:441–
63.
97. Andersson G, Fagrell B, Holmgren K, Johnsson H, Ljungberg
B, Wilhelmsson S. Antithrombin III in patients with acute
deep vein thrombosis during heparin treatment (subcutaneous
and intravenous) and during and after treatment with oral cou-
marins. Thromb Res 1984;34:333–40.
98. O’Brien JR, Etherington MD. Effect of heparin and warfarin
on antithrombin III. Lancet 1977;2:1231.
99. Kottke-Marchant K, Duncan A. Antithrombin deficiency:
issues in laboratory diagnosis. Arch Pathol Lab Med 2002;
126:1326–36.
100. Conard J. Antithrombin activity and antigen. In: Jespersen J,
Bertina RM, Haverkate F, editors. Laboratory Techniques in
Thrombosis A Manual 2nd Revised Edition of the ECAT
Assay Procedures. Dordrecht: Kluwer, 1999:121–8.
